Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
- Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
- Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop